AbbVie says that Elahere is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

Upon exercise of the option, AbbVie would pay Aldeyra a $100M upfront cash payment, less previously paid option fees of $6M. In addition, Aldeyra would be eligible to receive up to $300 million in ...

Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular ...

Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...

Upon exercise of the option, AbbVie would pay Aldeyra a $100 million upfront cash payment, less previously paid option fees of $6 million. In addition, Aldeyra would be eligible to receive up to $300 ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...

Patent expirations from Brukinsa’s existing competitors may bring biosimilar drugs into the field before Brukinsa reaches its full commercial potential. BeiGene may lose the lawsuit to AbbVie over ...

Pharma industry veteran, Thomas Gordon tapped to lead network sales teamMontvale, NJ, Nov. 12, 2024 (GLOBE NEWSWIRE) -- As a ...

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...